Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa.

The New England Journal of Medicine
James G HakimREALITY Trial Team

Abstract

In sub-Saharan Africa, among patients with advanced human immunodeficiency virus (HIV) infection, the rate of death from infection (including tuberculosis and cryptococcus) shortly after the initiation of antiretroviral therapy (ART) is approximately 10%. In this factorial open-label trial conducted in Uganda, Zimbabwe, Malawi, and Kenya, we enrolled HIV-infected adults and children 5 years of age or older who had not received previous ART and were starting ART with a CD4+ count of fewer than 100 cells per cubic millimeter. They underwent simultaneous randomization to receive enhanced antimicrobial prophylaxis or standard prophylaxis, adjunctive raltegravir or no raltegravir, and supplementary food or no supplementary food. Here, we report on the effects of enhanced antimicrobial prophylaxis, which consisted of continuous trimethoprim-sulfamethoxazole plus at least 12 weeks of isoniazid-pyridoxine (coformulated with trimethoprim-sulfamethoxazole in a single fixed-dose combination tablet), 12 weeks of fluconazole, 5 days of azithromycin, and a single dose of albendazole, as compared with standard prophylaxis (trimethoprim-sulfamethoxazole alone). The primary end point was 24-week mortality. A total of 1805 patients (1733 adults ...Continue Reading

References

Dec 18, 2003·Population Health Metrics·Jennifer JelsmaPaul Kind
Mar 17, 2010·BMC Infectious Diseases·Joseph N JarvisThomas S Harrison
Aug 5, 2010·AIDS·Morna CornellUNKNOWN International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) Collaboration
Oct 11, 2011·The Lancet Infectious Diseases·Rosalind Parkes-RatanshiUNKNOWN Cryptococcal Trial Team
Sep 14, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A Sarah WalkerUNKNOWN DART and ARROW trial teams
Mar 15, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Christian L ColesSheila West
Jul 12, 2014·The New England Journal of Medicine·Nicholas I PatonUNKNOWN EARNEST Trial Team
Dec 4, 2014·The Lancet Infectious Diseases·Nathan FordGeorge K Siberry
Jul 21, 2015·The New England Journal of Medicine·UNKNOWN INSIGHT START Study GroupJames D Neaton
Jul 21, 2015·The New England Journal of Medicine·UNKNOWN TEMPRANO ANRS 12136 Study GroupXavier Anglaret

❮ Previous
Next ❯

Citations

Mar 24, 2018·Current Opinion in Infectious Diseases·Andrew J McArdleAubrey J Cunnington
Mar 8, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lisa FrigatiNathan Ford
Mar 8, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Frank A PostUNKNOWN Reduction of EArly mortaLITY in HIV-infected adults and children starting antiretroviral therapy (REALITY) Trial Team
Mar 8, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Abraham SiikaUNKNOWN REALITY Trial Team
Mar 8, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Nathan FordUNKNOWN Guideline Development Group for Managing Advanced HIV Disease and Rapid Initiation of Antiretroviral Therapy
Jul 12, 2018·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Deborah FordDiana M Gibb
Jul 18, 2018·International Health·Charles B HolmesElvin Geng
Aug 23, 2018·African Journal of AIDS Research : AJAR·Rachel KawumaUNKNOWN REALITY Trial Team
Aug 30, 2018·The Cochrane Database of Systematic Reviews·Ajibola A AwotiwonIngrid Eshun-Wilson
Dec 7, 2018·The Cochrane Database of Systematic Reviews·Chantal MigoneIngrid Eshun-Wilson
Jan 22, 2019·Expert Opinion on Pharmacotherapy·James J C Nuttall
Sep 10, 2018·The British Journal of Ophthalmology·David HeidenW Lawrence Drew
Mar 21, 2019·JMIR Public Health and Surveillance·Brian RiceJames Hargreaves
Jun 18, 2019·The Cochrane Database of Systematic Reviews·Alberto Mateo-UrdialesIngrid Eshun-Wilson
Apr 26, 2019·Biomédica : revista del Instituto Nacional de Salud·Mónica María Lopera, Yesly Lemos
Jan 9, 2020·Journal of the International AIDS Society·Lucia González FernándezSusan Swindells
Mar 19, 2020·International Journal of STD & AIDS·Cielo Yaneth Ríos-HincapiéZulma Vanessa Rueda
May 6, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Nathan FordCarmen Perez-Casas
Jan 27, 2018·Open Forum Infectious Diseases·Mahsa AbassiDavid R Boulware
Apr 29, 2020·The American Journal of Tropical Medicine and Hygiene·John D HartRobin L Bailey
Aug 28, 2020·The Cochrane Database of Systematic Reviews·Alexander W KayAnna M Mandalakas
Feb 28, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Christine KellySaye Khoo
Oct 5, 2018·Current Opinion in HIV and AIDS·Nathan FordHaileyesus Getahun
Sep 11, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Irini SeretiFredrick Sawe
Jul 21, 2017·The New England Journal of Medicine·Nathan Ford, Meg Doherty
Dec 7, 2018·Current Opinion in Infectious Diseases·David S LawrenceJoseph N Jarvis
Mar 29, 2020·Journal of the International AIDS Society·Simon M WalkerUNKNOWN REALITY trial team
May 7, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Esther NasuunaJoanita Kigozi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Related Papers

The New England Journal of Medicine
TEMPRANO ANRS 12136 Study GroupXavier Anglaret
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Azure T MakadzangeJames G Hakim
The New England Journal of Medicine
INSIGHT START Study GroupJames Neaton
The New England Journal of Medicine
Graham R FosterASTRAL-3 Investigators
The New England Journal of Medicine
Mutsawashe Bwakura-DangarembiziAndrew J Prendergast
© 2021 Meta ULC. All rights reserved